Physician profile
Debra J Moses
NPI 1639308398
$11,646.00
in general payments reported to CMS, 2019-2025
63 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,840 · 2020: $1,539 · 2021: $1,705 · 2022: $1,876 · 2023: $1,625 · 2024: $1,401 · 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,678 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,677.86 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,444.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,039.31 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $895.76 | 2019-2025 | |
| Lilly USA, LLC | $837.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $600.76 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $549.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.57 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $414.06 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $383.85 | 2020-2025 | Rexulti |
| Pfizer INC. | $332.28 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $323.72 | 2019-2025 | |
| Astellas Pharma US INC | $280.37 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $275.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $259.70 | 2020-2024 | Xarelto |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.